Download PDF

Other users also viewed these articles

Reducing hyperuricemic events with SGLT2 inhibitors: An updated systematic review with meta-regression Hamlet Ghukasyan; Denilsa Dinis Pedro Navalha; Ignacio Pérez Romero; Maria Vitória Prato Wolwacz; Artur Ghahramanyan; Cristiane Wen Tsing Ngan; Maria Helena Siqueira Tavares de Melo; Caroline Serafim Dagostin; Luis Gómez-Lechón Quirós;
Endocrinol Diabetes Nutr. 2025;72:26-36
Consensus document for lipid profile testing and reporting in Spanish clinical laboratories Teresa Arrobas Velilla; Carlos Guijarro; Raquel Campuzano Ruiz; Manuel Rodríguez Piñero; José Francisco Valderrama Marcos; Antonio M. Botana López; Ana Morais López; José Antonio García Donaire; Juan Carlos Obaya; Luis Castilla Guerra; Vicente Pallares Carratalá; Isabel Egocheaga Cabello; Mercedes Salgueira Lazo; María Mar Castellanos Rodrigo; José María Mostaza Prieto; Juan José Gómez Doblas; Antonio Buño Soto;
Endocrinol Diabetes Nutr. 2023;70:501-10
Lipid-lowering drug therapy for reducing cardiovascular risk in diabetes. A clinical view of the Cardiovascular Disease Working Group of the Spanish Diabetes Society Juan Pedro-Botet; Francisco Arrieta; Manuel Botana; José A. Gimeno-Orna; José I. Martínez-Montoro; Emilio Ortega-Martínez de Victoria; Josep Ribalta; Víctor Sánchez-Margalet; Antonio Pérez-Pérez;
Endocrinol Diabetes Nutr. 2025;72: